Anne M. Rompalo, MD

CRS:

JHU

Role:

Investigators

Position:

HPTN Site Leader

Email:

arompalo@jhmi.edu

Anne M. Rompalo, M.D., Sc.M.  Dr. Rompalo is a Professor of Medicine and Gynecology at the Johns Hopkins University School of Medicine (JHUSOM), with joint appointments in Epidemiology, International Health and Population, Family and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health.  She is Medical Director of the CDC-sponsored Sexually Transmitted Diseases (STD)/HIV Prevention Training Center at Johns Hopkins (PTC), and has previously been Acting Medical Director of the Baltimore City Health Departments STD Clinics and Medical Director of the Office of Population Affairs Male Training Center.  She has over 15 years of experience as the Medical Director of the STD/HIV PTC, and has been a key investigator on several studies focused on the natural history of HIV among women including the HERS (HIV Epidemiology Research Study) and HIV prevention among U.S. women at high risk for infection, HPTN 064 trial. 

  • Investigator of Record, HPTN 064
  • Investigator of Record, HPTN 083

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More